Effect of an aerosol delivery system on bronchodilator activity.
Metered dose inhalers (MDIs) are often used incorrectly by patients who find difficulty using MDI for drug inhalation. The study was performed in 11 asthmatic patients in four days in order to evaluate the efficiency of a new Drug Delivery System (DDS-InspirEase) for metered dose inhalers. Clenbuterol was administered via DDS and via conventional MDI in a randomized manner. On the first two days, DDS and MDI were used by patients without any physician's help. On the subsequent days, clenbuterol was administered via DDS and via conventional MDI directly by the physician. FEV1 and MEF75 values were measured 15', 30', one hour, and two hours post-drug inhalation. Statistical analysis (ANOVA) showed that clenbuterol delivered by DDS, administered by patients or by physician, produced a greater increase in FEV1 values (P less than .05) and MEF75 values (P less than .01) in comparison to the conventional MDI on each test day. No significant differences existed between physician or patient administration of clenbuterol with DDS and MDI. The results showed a greater bronchodilator effect obtained by clenbuterol delivered by DDS.
Crimi
N
N
Institute of Respiratory Diseases, University of Catania, Catania, Italy.
Palermo
F
F
Cacopardo
B
B
Vancheri
C
C
Oliveri
R
R
Polosa
R
R
Mistretta
A
A
D000328:Adult; D000336:Aerosols; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001993:Bronchodilator Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002976:Clenbuterol / Q000008:administration & dosage / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D005541:Forced Expiratory Volume; D006801:Humans; D008448:Maximal Expiratory Flow Rate; D009330:Nebulizers and Vaporizers
D000336:Aerosols; D001993:Bronchodilator Agents; D002976:Clenbuterol